Fremanezumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Fremanezumab" in English language version.

refsWebsite

Global rank English rank

3nih.gov

4^th place

2drugs.com

399^th place

333^rd place

2europa.eu

68^th place

117^th place

1hres.ca

low place

1canada.ca

1,712^th place

1,063^rd place

1nice.org.uk

3,258^th place

2,666^th place

1medicines.org.uk

3,823^rd place

2,387^th place

1infobae.com

303^rd place

1,010^th place

1doi.org

2^nd place

1handle.net

102^nd place

76^th place

1springer.com

274^th place

309^th place

1web.archive.org

1^st place

1tevapharm.com

low place

1businesswire.com

615^th place

407^th place

1mdmag.com

low place

1clinicaladvisor.com

low place

1fda.gov

447^th place

338^th place

businesswire.com

"Teva's AJOVY Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults" (Press release). Teva Pharmaceutical Industries Ltd. 1 April 2019. Retrieved 6 April 2019 – via Business Wire.

canada.ca

health-products.canada.ca

"Ajovy Product information". Health Canada. Retrieved 31 May 2022.

clinicaladvisor.com

"Novel class of preventive treatments for migraine - Clinical Advisor". 18 May 2020.

doi.org

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. (May 2018). "Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial". JAMA. 319 (19): 1999–2008. doi:10.1001/jama.2018.4853. PMC 6583237. PMID 29800211.

drugs.com

"Fremanezumab (Ajovy) Use During Pregnancy". Drugs.com. 3 October 2018. Retrieved 2 April 2020.
"Fremanezumab-vfrm Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 15 July 2019.

europa.eu

ema.europa.eu

"Ajovy EPAR". European Medicines Agency (EMA). 29 January 2019. Retrieved 2 April 2020.
"Ajovy: EPAR - Product Information" (PDF). European Medicines Agency. 17 April 2019.

fda.gov

accessdata.fda.gov

"AJOVY prescribing information" (PDF). Drugs@FDA: FDA-Approved Drugs. Retrieved 11 July 2020.

handle.net

hdl.handle.net

World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77". WHO Drug Information. 31 (1): 61–150. hdl:10665/330984.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Ajovy". Health Canada. Retrieved 29 May 2022.

infobae.com

"Migraña: en qué consiste el nuevo tratamiento para esta enfermedad frecuente e incapacitante". 12 September 2021.

mdmag.com

"Teva Pulls Out of Chronic Cluster Headache Trial of Fremanezumab". MD Magazine. Retrieved 19 June 2018.

medicines.org.uk

"Ajovy (fremanezumab) 225 mg Pre-filled Syringe for Injection - Summary of Product Characteristics (SmPC)". (emc). Retrieved 27 September 2021.

nice.org.uk

bnf.nice.org.uk

"Fremanezumab". NICE - National Institute for Health and Care Excellence. Retrieved 25 June 2021.

nih.gov

dailymed.nlm.nih.gov

"Ajovy- fremanezumab-vfrm injection". DailyMed. U.S. National Library of Medicine. 5 February 2020. Retrieved 2 April 2020.

ncbi.nlm.nih.gov

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. (May 2018). "Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial". JAMA. 319 (19): 1999–2008. doi:10.1001/jama.2018.4853. PMC 6583237. PMID 29800211.

pubmed.ncbi.nlm.nih.gov

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. (May 2018). "Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial". JAMA. 319 (19): 1999–2008. doi:10.1001/jama.2018.4853. PMC 6583237. PMID 29800211.

springer.com

adis.springer.com

"Fremanezumab - Teva Pharmaceutical".

tevapharm.com

"Teva Announces U.S. Approval of AJOVY (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults". Teva Pharmaceutical Industries Ltd Pharmaceutical Industries Ltd. Archived from the original on 8 October 2018. Retrieved 7 October 2018.

web.archive.org

"Teva Announces U.S. Approval of AJOVY (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults". Teva Pharmaceutical Industries Ltd Pharmaceutical Industries Ltd. Archived from the original on 8 October 2018. Retrieved 7 October 2018.